Telesis Bio to Present at RNA Leaders Europe Congress
14 mars 2023 06h00 HE
|
Telesis Bio
SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced they will be showcasing their...
Telesis Bio to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 21, 2023
09 mars 2023 16h30 HE
|
Telesis Bio
SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its fourth quarter...
Telesis Bio to Present at the Cowen 43rd Annual Healthcare Conference
27 févr. 2023 09h00 HE
|
Telesis Bio
SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that Todd R. Nelson, PhD, the...
Telesis Bio Releases BioXp® Select mRNA Synthesis Kit to Expand the Utility, Speed, and Impact of Its Automated Synthetic Biology Workstation
16 févr. 2023 09h00 HE
|
Telesis Bio
SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the availability of its BioXp® Select...
Telesis Bio Pre-Announces Preliminary Fourth Quarter Financial Results
09 janv. 2023 09h00 HE
|
Telesis Bio
-- Record revenue of $9M in 4QFY22; Increase of 191% over 4QFY21 -- BioXp® Revenue increased by 131% to $3M, in 4QFY22 over 4QFY21 -- Successful achievement of first technical milestone with Pfizer...
Telesis Bio Inc. Reports Third Quarter 2022 Financial Results
08 nov. 2022 16h10 HE
|
Telesis Bio
-- Record revenue of $6.7M in 3QFY22; Increase of 140% over $2.8M 3QFY 2021 -- BioXp® Kit Revenue increased to $884k, or 69% in 3QFY22 over 3QFY2021 -- Increases revenue guidance to $23 million to...
Telesis Bio to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 8
02 nov. 2022 16h19 HE
|
Telesis Bio
SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022...
Telesis Bio und Cellibre kündigen Zusammenarbeit an, um die Entwicklung des künftigen BioXp® DBC-Instruments zu optimieren
19 oct. 2022 17h33 HE
|
Telesis Bio
SAN DIEGO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), ein führendes Unternehmen für automatisierte Multi-Omics- und synthetische Biologielösungen, und Cellibre, ein führendes...
Telesis Bio et Cellibre annoncent une collaboration pour optimiser le développement du futur instrument BioXp® DBC
19 oct. 2022 17h33 HE
|
Telesis Bio
SAN DIEGO, 19 oct. 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq : DNAY), leader des solutions de biologie synthétique et multi-omique automatisées, et Cellibre, une société de premier plan...
Telesis Bio and Cellibre Announce Collaboration to Optimize Development of Future BioXp® DBC instrument
19 oct. 2022 09h00 HE
|
Telesis Bio
SAN DIEGO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, and Cellibre, a leading manufacturing technology company,...